Docetaxel

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg

Disponibbli minn:

REX Medical Ltd

INN (Isem Internazzjonali):

Docetaxel trihydrate 25.177 mg (equivalent to anhydrous docetaxel 20mg)

Dożaġġ:

20 mg/mL

Għamla farmaċewtika:

Concentrate for infusion

Kompożizzjoni:

Active: Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Unitajiet fil-pakkett:

Vial, glass, Diluent, 1.5 mL

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Cipla Ltd

Indikazzjonijiet terapewtiċi:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Vial, glass, Diluent - 1.5 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 20 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Data ta 'l-awtorizzazzjoni:

2006-06-23